Dr. Reddy’s Laboratories is currently trading at Rs. 2752.00, up by 3.60 points or 0.13% from its previous closing of Rs. 2748.40 on the BSE.
The scrip opened at Rs. 2747.65 and has touched a high and low of Rs. 2777.90 and Rs. 2745.00 respectively. So far 7042 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2965.20 on 02-May-2019 and a 52 week low of Rs. 2065.30 on 15-Feb-2019.
Last one week high and low of the scrip stood at Rs. 2777.90 and Rs. 2531.00 respectively. The current market cap of the company is Rs. 45761.52 crore.
The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 44.50% and 14.44% respectively.
Dr. Reddy's Laboratories has launched Fosaprepitant Injection in the U.S. Market, the therapeutic generic equivalent of EMEND (fosaprepitant) for injection, approved by the U.S. Food and Drug Administration (USFDA).
The EMEND for Injection brand had U.S. sales of approximately $279 million MAT for the most recent twelve months ending in July 2019 according to IQVIA Health.
Dr. Reddy's Fosaprepitant for Injection is available in 150 mg single-dose vial for reconstitution.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.